Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc covers the period ending June 2015. It serves as a replacement for an original announcement released on May 22, 2015, and provides a notification regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure and voting rights.
- Issued Share Capital (as of May 31, 2015): 5,357,802,400 Ordinary Shares of 25p each.
- Treasury Shares: 491,515,950 Ordinary Shares.
- Total Voting Rights: 4,866,286,450.
Material Changes
The filing does not report material changes in financial performance or operations compared to prior periods. It updates the market on the specific calculation of voting rights to assist shareholders in determining notification requirements under Financial Conduct Authority rules.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory notification of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (4,866,286,450) against the issued share capital minus treasury shares.
- Confirm the date of the capital structure data (May 31, 2015) for accurate denominator calculations in ownership notifications.
- Note that this filing replaces a previous announcement from May 22, 2015.